News & Updates
Filter by Specialty:
Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
In the final progression-free survival (PFS) analysis of the GEMSTONE-301 study, sugemalimab demonstrated sustained efficacy and safety as consolidation treatment for individuals with unresectable stage III non-small cell lung cancer (NSCLC) whose disease had not progressed following either concurrent chemoradiotherapy (cCRT) or sequential CRT (sCRT).
Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
07 Oct 2022Early sleep, longer time in bed tied to dementia risk in older adults
Older adults who sleep before 9 P.M. and have prolonged sleep duration appear to be at an increased risk of dementia, a recent study has found.
Early sleep, longer time in bed tied to dementia risk in older adults
07 Oct 2022Disease flare not uncommon in SLE patients on dialysis
Nearly one in four patients with systemic lupus erythematosus (SLE) suffer a disease flare during dialysis, with most having haematological manifestations such as thrombocytopaenia, a study has shown.
Disease flare not uncommon in SLE patients on dialysis
06 Oct 2022Dapagliflozin prevents worsening heart failure, CV death
Dapagliflozin is a safe treatment to reduce the risk of worsening heart failure (HF) or cardiovascular death both in patients with and without history of recent HF hospitalization, a study has shown.
Dapagliflozin prevents worsening heart failure, CV death
06 Oct 2022Smartphone app fails to boost MVPA in diabetics
Among patients with type 2 diabetes (T2D), use of the smartphone-based app InterWalk does not improve objective measures of moderate-to-vigorous physical activity (MVPA), according to a study.